Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 175 Innovation Boulevard WILMINGTON DE 19805 |
Tel: | N/A |
Website: | https://preludetx.com |
IR: | See website |
Key People | ||
Jane Huang President, Chief Medical Officer | Krishna Vaddi Chief Executive Officer, Founder, Director | Bryant D. Lim Interim Chief Financial Officer, Chief Legal Officer and Corporate Secretary |
Andrew P. Combs Executive Vice President, Head of Chemistry | Peggy A. Scherle Chief Scientific Officer |
Business Overview |
Prelude Therapeutics Incorporated is a clinical-stage fully integrated oncology company built on a foundation of drug discovery to deliver novel precision cancer medicines to underserved patients. It has developed a diverse pipeline consisting of multiple distinct programs: kinases, targeted protein degraders, and precision antibody drug conjugates. Its product candidates include PRT3789, PRT2527 and PRT3645. PRT3789 is a highly selective degrader of SMARCA2 protein, which along with SMARCA4, controls gene regulation through chromatin remodeling. Its CDK9 program is an essential regulator of cancer-promoting transcriptional programs, including those driven by MCL1, MYC and MYB. PRT3645 is a brain and tissue penetrant molecule that potently targets CDK4/6 with a biased selectivity for CDK4. PRT2527 is designed to be a potent and selective CDK9 inhibitor. Its MCL1 candidate, PRT1419, is designed to be a potent and selective inhibitor of the anti-apoptotic protein, MCL1. |
Financial Overview |
For the fiscal year ended 31 December 2023, Prelude Therapeutics Inc revenues was not reported. Net loss increased 6% to $121.8M. Higher net loss reflects Research and development increase of 12% to $90.8M (expense), Stock-based Compensation in R&D increase of 9% to $12.6M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$2.44 to -$2.02. |
Employees: | 128 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | N/A |
Annual revenue (TTM): | $0.00M as of Dec 31, 2023 |
EBITDA (TTM): | -$131.11M as of Dec 31, 2023 |
Net annual income (TTM): | -$121.83M as of Dec 31, 2023 |
Free cash flow (TTM): | -$110.58M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 54,920,594 as of Feb 9, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |